Oral Dietary Fucoxanthin Rich Supplement for Liver Health
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Tair Lapidot, Dr
- Phone Number: +972548095209
- Email: tair@algatech.com
Study Contact Backup
- Name: Marina Beder
- Email: marinabe@asaf.health.gov.il
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adults > 18 years
- Willing to sign an informed consent to participate in the study.
- Non-smokers.
- Blood results above the normal range in hepatic function testing consisting of panels containing ALT, AST, ALP, total bilirubin and albumin and abdominal ultrasonography.
- Over-weight (BMI ≥ 27 kg/m2) who fulfill the criteria of the National Cholesterol Education Program (NCEP) metabolic syndrome.
Exclusion Criteria:
- Pregnancy.
- Presence of gastrointestinal or mental disorders, diabetes mellitus, alcohol abuse, weight-loss treatment, bariatric surgery, unusual diets (vegetarian, vegan), daily usage of antioxidants dietary supplements at the last 4 months (for subjects in stage 2 of the study).
- Serious medical conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fucovital
capsules of a dietary supplement rich with fucoxanthin from microalgae extract
|
Microalgae oil extract
Other Names:
|
|
Placebo Comparator: Placebo
capsules of an edible oil
|
Microalgae oil extract
Other Names:
Edible oil
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver function test: Serum Alanine transaminase (ALT)
Time Frame: week 0,12,24
|
Change from baseline of liver enzymes
|
week 0,12,24
|
|
Liver function test: Aspartate transaminase (AST)
Time Frame: week 0,12,24
|
Change from baseline of liver enzymes
|
week 0,12,24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver function test:Blood gamma-glutamyl transferase (GGT)
Time Frame: week 0,12,24
|
change from baseline
|
week 0,12,24
|
|
Liver function test:Blood albumin
Time Frame: week 0,12,24
|
change from baseline
|
week 0,12,24
|
|
Liver function test: Blood bilirubin
Time Frame: week 0,12,24
|
change from baseline
|
week 0,12,24
|
|
Hepatic steatosis
Time Frame: 0, 24 week
|
Change from baseline by ultrasound
|
0, 24 week
|
|
Weight
Time Frame: week 0,12,24
|
Change from baseline
|
week 0,12,24
|
|
Waist circumference
Time Frame: week 0,12,24
|
Change from baseline
|
week 0,12,24
|
|
Serum lipid profile
Time Frame: week 0,12,24
|
Change from baseline total cholesterol, triglycerides, low density lipoprotein (LDL) (HDL) fractions
|
week 0,12,24
|
|
Blood glucose status
Time Frame: week 0,12,24
|
Change from baseline of HbA1c
|
week 0,12,24
|
|
Inflammation
Time Frame: week 0,12,24
|
Change from baseline of CRP
|
week 0,12,24
|
|
Kidney function test: serum creatinine
Time Frame: week 0,12,24
|
Change from baseline
|
week 0,12,24
|
|
Kidney function test: Glomerular Filtration Rate(GFR)
Time Frame: week 0,12,24
|
Change from baseline
|
week 0,12,24
|
|
Kidney function test: Blood Urea Nitrogen
Time Frame: week 0,12,24
|
Change from baseline
|
week 0,12,24
|
|
Dietary supplement level in the blood
Time Frame: week 0,6 or 12,24
|
Determination of Fucoxanthin metabolite in plasma by LC-MS/MS
|
week 0,6 or 12,24
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Haim Shirin, Prof., Director Institute of Gastroenterolgy, Liver Diseases and Nutrition
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Clinical protocol FUCO 02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.